Uncategorized
John Santilli quoted in Modern Medicine: FDA approves Cyramza in combination with paclitaxel for advanced gastric cancer after prior chemotherapy
“Cyramza, approved earlier this year for stomach cancer, is a key product in Lilly’s oncology portfolio,” said John Santilli, of Access Market Intelligence, which provides market intelligence to the pharmaceutical and healthcare industries. “With the colorectal cancer market becoming increasingly crowded, Lilly will need to review the pricing strategy for Cyramza to make sure the drug remains competitive in this market.”
